[{"orgOrder":0,"company":"Navrongo Health Research Centre, Ghana","sponsor":"DBL -Institute for Health Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GHANA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Navrongo Health Research Centre, Ghana","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navrongo Health Research Centre, Ghana \/ DBL -Institute for Health Research and Development","highestDevelopmentStatusID":"11","companyTruncated":"Navrongo Health Research Centre, Ghana \/ DBL -Institute for Health Research and Development"},{"orgOrder":0,"company":"Centre for Global Health Research, Ghana","sponsor":"London School of Hygiene & Tropical Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GHANA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Centre for Global Health Research, Ghana","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Global Health Research, Ghana \/ London School of Hygiene & Tropical Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Centre for Global Health Research, Ghana \/ London School of Hygiene & Tropical Medicine"},{"orgOrder":0,"company":"Bandim Health Project","sponsor":"Karolinska Institutet","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GUINEA-BISSAU","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bandim Health Project","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bandim Health Project \/ Karolinska Institutet","highestDevelopmentStatusID":"11","companyTruncated":"Bandim Health Project \/ Karolinska Institutet"},{"orgOrder":0,"company":"Centro de Investigacao em Saude de Manhica","sponsor":"World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MOZAMBIQUE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centro de Investigacao em Saude de Manhica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centro de Investigacao em Saude de Manhica \/ World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique","highestDevelopmentStatusID":"1","companyTruncated":"Centro de Investigacao em Saude de Manhica \/ World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Artemether","moa":"||Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ GHIT Fund","highestDevelopmentStatusID":"10","companyTruncated":"Fosun Pharmaceutical \/ GHIT Fund"},{"orgOrder":0,"company":"Medicines for Malaria Venture","sponsor":"SGS Life Sciences | Institute of Tropical Medicine, Belgium | Swiss BioQuant | PrimeVigilance Ltd | Sanaria | IQVIA | FGK Representative Service","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medicines for Malaria Venture","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicines for Malaria Venture \/ SGS Life Sciences | Institute of Tropical Medicine, Belgium | Swiss BioQuant | PrimeVigilance Ltd | Sanaria | IQVIA | FGK Representative Service","highestDevelopmentStatusID":"6","companyTruncated":"Medicines for Malaria Venture \/ SGS Life Sciences | Institute of Tropical Medicine, Belgium | Swiss BioQuant | PrimeVigilance Ltd | Sanaria | IQVIA | FGK Representative Service"},{"orgOrder":0,"company":"Medicines for Malaria Venture","sponsor":"Southern Star Research | Nucleus Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medicines for Malaria Venture","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicines for Malaria Venture \/ Southern Star Research | Nucleus Network","highestDevelopmentStatusID":"6","companyTruncated":"Medicines for Malaria Venture \/ Southern Star Research | Nucleus Network"},{"orgOrder":0,"company":"LondonPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LondonPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Spray","sponsorNew":"LondonPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LondonPharma \/ Undisclosed"},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"Medical Research and Training Centre, Mali | University of Ouagadougou, Burkina Faso | MRC Unit, The Gambia | Navrongo Health Research Centre, Ghana | Liverpool School of Tropical Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London School of Hygiene & Tropical Medicine \/ Medical Research and Training Centre, Mali | University of Ouagadougou, Burkina Faso | MRC Unit, The Gambia | Navrongo Health Research Centre, Ghana | Liverpool School of Tropical Medicine","highestDevelopmentStatusID":"11","companyTruncated":"London School of Hygiene & Tropical Medicine \/ Medical Research and Training Centre, Mali | University of Ouagadougou, Burkina Faso | MRC Unit, The Gambia | Navrongo Health Research Centre, Ghana | Liverpool School of Tropical Medicine"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Artemether","moa":"||Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Artemether","moa":"||Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Neopharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.A.E","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Neopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neopharma \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Neopharma \/ Parexel"},{"orgOrder":0,"company":"Proto Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Proto Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Proto Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Proto Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Proto Pharma","sponsor":"Xidea Solutions Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Proto Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Proto Pharma \/ Xidea Solutions Limited","highestDevelopmentStatusID":"10","companyTruncated":"Proto Pharma \/ Xidea Solutions Limited"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Center for Malariology, Parasitology, and Entomology | The National Institute of Public Health | Health Poverty Action","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Center for Malariology, Parasitology, and Entomology | The National Institute of Public Health | Health Poverty Action","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Center for Malariology, Parasitology, and Entomology | The National Institute of Public Health | Health Poverty Action"},{"orgOrder":0,"company":"Centers for Disease Control and Prevention","sponsor":"Ethiopian Health and Nutrition Research Institute | Federal Minstry of Health of Ethiopia | Columbia University | Oromia Regional Health Bureau, Ethiopia | United States Agency for International Development | Menzies School of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Centers for Disease Control and Prevention","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centers for Disease Control and Prevention \/ Ethiopian Health and Nutrition Research Institute | Federal Minstry of Health of Ethiopia | Columbia University | Oromia Regional Health Bureau, Ethiopia | United States Agency for International Development | Menzies School of Health Research","highestDevelopmentStatusID":"11","companyTruncated":"Centers for Disease Control and Prevention \/ Ethiopian Health and Nutrition Research Institute | Federal Minstry of Health of Ethiopia | Columbia University | Oromia Regional Health Bureau, Ethiopia | United States Agency for International Development | Menzies School of Health Research"},{"orgOrder":0,"company":"Universidad Nacional de Colombia","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"COLOMBIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Universidad Nacional de Colombia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad Nacional de Colombia \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Universidad Nacional de Colombia \/ Sanofi"},{"orgOrder":0,"company":"Professor Anders Bj\u00f6rkman","sponsor":"Zanzibar Malaria Control Programme | World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Professor Anders Bj\u00f6rkman","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Professor Anders Bj\u00f6rkman \/ Zanzibar Malaria Control Programme | World Health Organization","highestDevelopmentStatusID":"11","companyTruncated":"Professor Anders Bj\u00f6rkman \/ Zanzibar Malaria Control Programme | World Health Organization"}]
Find Clinical Drug Pipeline Developments & Deals for Artemether
Details :
Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries.
Details :
Coartem® (artemether-lumefantrine) a novel formulation which is being developed forthe treatment of babies weighing less than 5kg with malaria.
Details :
The financing will be used for a clinical phase III trial for a fixed-dose combination of artemether-lumefantrine-amodiaquine drug (three existing antimalarial drugs already developed, marketed and sold) against malaria.
Details :
Artemether is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malaria, Falciparum.
Details :
Artemether is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Malaria.
Details :
Artemether is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Malaria, Falciparum.
Sponsor :
European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante
Details :
Artemether is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Malaria, Falciparum.
Sponsor :
European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante
Details :
Artemether is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Malaria.
Details :
Artemether is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malaria, Falciparum.
Reset All
